FDA Advisory Committee Recommends Approval of Pfizer’s RSV Vaccine

March 1, 2023

Pfizer received a recommendation from the US Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee (VRPAC) for its respiratory syncytial virus (RSV) vaccine, dubbed RSVpreF. The recommendation is for adults over 60 years old, the group most impacted by the recent wave of RSV infections.

According to Emily Kimber, “RSV is a contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe infections in infants, older adults and individuals with certain chronic medical conditions. In the US, it is estimated that RSV infections in older adults account for approximately 60,000 to 160,000 hospitalisations and 6,000 to 13,000 deaths each year. There are currently no prophylactic, therapeutic, or vaccine options for older adults and the medical community is limited to offering only supportive care for adults with the illness.”

To read more, click here.